RingCentral ‘s Most Resilient Enterprise Segment Gives In To Demand Weakness, Analysts Flag Post Q4 Disappointment

Raymond James analyst Brian Peterson maintained RingCentral Inc (NYSE: RNG) with a Strong Buy and 

Raymond James analyst Brian Peterson maintained RingCentral Inc (NYSE:RNG) with a Strong Buy and lowered the price target from $75 to $62.

The 4Q revenue of $524.7 million (+17% Y/Y; +19% CC) fell modestly below Peterson’s $526.9 million estimate and consensus of $527.4M. Subscription revenue grew 19% Y/Y (+21% CC) to $501.6 million, slightly missing the analyst’s $505.0 million (consensus of $504.3 million).

The 4Q22 results reflected a softening demand environment and decelerating growth across each customer segment. Even the resilient enterprise segment fell to 21% growth. 

Enterprise ARR remained the relative bright spot at +21% (including multiple 7-figure deals), although sales cycles and deal sizes remained under pressure. 

Management believes the revised Avaya partnership will provide a better ramp toward the ACO partnership. RingCentral also announced a partnership with Amazon.Com Inc (NASDAQ:AMZN) AWS while referencing continued Q/Q growth with Mitel.

The demand weakness manifested in an 11% subscription revenue growth outlook well below the street. However, this could prove conservative, with the 1Q outlook calling for 14-15% growth and easier comps throughout the year. 

While FCF has been volatile, management indicated that “normalized” FCF could double by 2024, suggesting that FCF could reach ~$300 million in 2024. The analyst believed that the dynamic could provide a path to value creation for RNG, while investors may question the balance of growth and profitability in that FCF algorithm.

Needham analyst Ryan Koontz reiterated a Hold rating pending greater confidence that subscription growth has bottomed.

Koontz saw the company adopting to the new market demands for higher profitability and cash flow as it arranged $600 million in new debt to refinance $1.6 billion due in ’25 and ’26. 

The analyst’s C23 revenue estimate drops (-4%) but EPS increases by +$0.19. 

Price Action: RNG shares traded lower by 19.50% at $38.97 on the last check Thursday.

Total
0
Shares
Related Posts
Read More

GSK Announced Blenrep DREAMM-3 Phase III Did Not Meet Primary Endpoint of Progression-free Survival

GSK plc (LSE/NYSE: GSK) today announced that DREAMM-3, the phase III open-label, randomised head-to-head superiority trial of Blenrep (belantamab mafodotin) monotherapy versus pomalidomide in combination with low dose dexamethasone (PomDex) in patients with relapsed or refractory multiple myeloma (RRMM), did not meet its primary endpoint of progression-free survival (PFS).

GSK